VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIVGet Free Report) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

VBI Vaccines stock opened at $0.58 on Friday. The business has a 50 day moving average of $0.62 and a 200-day moving average of $0.72. VBI Vaccines has a 1 year low of $0.45 and a 1 year high of $15.23. The company has a market capitalization of $13.74 million, a P/E ratio of -0.05 and a beta of 1.99.

Hedge Funds Weigh In On VBI Vaccines

Several institutional investors and hedge funds have recently added to or reduced their stakes in VBIV. State Street Corp lifted its holdings in VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company’s stock worth $26,920,000 after buying an additional 3,844,698 shares during the period. Millennium Management LLC boosted its holdings in VBI Vaccines by 211.7% in the second quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company’s stock valued at $1,440,000 after acquiring an additional 1,209,393 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in VBI Vaccines by 2.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,644,720 shares of the biopharmaceutical company’s stock valued at $2,731,000 after acquiring an additional 43,567 shares during the last quarter. Goldman Sachs Group Inc. increased its position in VBI Vaccines by 20.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,209,507 shares of the biopharmaceutical company’s stock valued at $978,000 after purchasing an additional 205,921 shares during the period. Finally, UBS Group AG raised its holdings in VBI Vaccines by 45.5% during the 1st quarter. UBS Group AG now owns 1,032,103 shares of the biopharmaceutical company’s stock worth $1,714,000 after purchasing an additional 322,957 shares during the last quarter. 19.08% of the stock is currently owned by institutional investors and hedge funds.

VBI Vaccines Company Profile

(Get Free Report)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

Read More

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.